Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 5 (May)

1. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.
   J Clin Invest, 115(5): 1121-9. [Abstract] [Full-text]
2. The Caregivers for Alzheimer's disease Problems Scale (CAPS): development of a new scale within the LASER-AD study.
   Age Ageing, 34(3): 287-90. [Abstract] [Full-text]
3. Lactate infusion fails to improve semantic categorization in Alzheimer's disease.
   Brain Res Bull, 65(6): 533-9. [Abstract] [Full-text]
4. The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population.
   Neurosci Lett, 380(3): 219-22. [Abstract] [Full-text]
5. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.
   FEBS Lett, 579(12): 2564-8. [Abstract] [Full-text]
6. Down syndrome, Alzheimer's disease and seizures.
   Brain Dev, 27(4): 246-52. [Abstract] [Full-text]
7. Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease.
   Int J Geriatr Psychiatry, 20(5): 485-8. [Abstract] [Full-text]
8. Childhood conduct problems, stages of Alzheimer's disease, and physical aggression against caregivers.
   Int J Geriatr Psychiatry, 20(5): 401-5. [Abstract] [Full-text]
9. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
   Int J Geriatr Psychiatry, 20(5): 459-64. [Abstract] [Full-text]
10. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications.
    Ann Neurol, 57(5): 695-703. [Abstract] [Full-text]
11. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Ann Neurol, 57(5): 721-9. [Abstract] [Full-text]
12. Neural correlates of impaired performance on the clock drawing test in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 390-6. [Abstract] [Full-text]
13. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 383-9. [Abstract] [Full-text]
14. Peripheral electrical stimulation in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 361-8. [Abstract] [Full-text]
15. The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.
    Dement Geriatr Cogn Disord, 19(5): 357-60. [Abstract] [Full-text]
16. Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment.
    Dement Geriatr Cogn Disord, 19(5): 349-56. [Abstract] [Full-text]
17. Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 345-8. [Abstract] [Full-text]
18. Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study.
    Dement Geriatr Cogn Disord, 19(5): 338-44. [Abstract] [Full-text]
19. Everyday memory impairment of patients with mild cognitive impairment.
    Dement Geriatr Cogn Disord, 19(5): 331-7. [Abstract] [Full-text]
20. Diagnostic accuracy of mini-mental status examination and revised hasegawa dementia scale for Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 324-30. [Abstract] [Full-text]
21. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting.
    Dement Geriatr Cogn Disord, 19(5): 305-15. [Abstract] [Full-text]
22. Motor function in subjects with mild cognitive impairment and early Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 299-304. [Abstract] [Full-text]
23. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(5): 256-65. [Abstract] [Full-text]
24. Evaluation of factors of importance for clinical dementia diagnosis.
    Dement Geriatr Cogn Disord, 19(5): 289-98. [Abstract] [Full-text]
25. Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease.
    Dement Geriatr Cogn Disord, 19(5): 276-81. [Abstract] [Full-text]
26. Pharmacology of Alzheimer's disease: appraisal and prospects.
    Dement Geriatr Cogn Disord, 19(5): 229-45. [Abstract] [Full-text]
27. Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease.
    Neurourol Urodyn, 24(3): 273-5. [Abstract] [Full-text]
28. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.
    Psychopharmacology (Berl), 179(3): 673-7. [Abstract] [Full-text]
29. Phosphorylation-specific prolyl isomerization: is there an underlying theme?
    Nat Cell Biol, 7(5): 435-41. [Abstract] [Full-text]
30. Variability of familial risk of Alzheimer disease across the late life span.
    Arch Gen Psychiatry, 62(5): 565-73. [Abstract] [Full-text]
31. Increased midkine levels in sera from patients with Alzheimer's disease.
    Prog Neuropsychopharmacol Biol Psychiatry, 29(4): 611-6. [Abstract] [Full-text]
32. Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia.
    Prog Neuropsychopharmacol Biol Psychiatry, 29(4): 603-10. [Abstract] [Full-text]
33. Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics.
    J Biol Chem, 280(18): 17792-7. [Abstract] [Full-text]
34. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.
    Nat Med, 11(5): 551-5. [Abstract] [Full-text]
35. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
    Nat Med, 11(5): 556-61. [Abstract] [Full-text]
36. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.
    Nat Med, 11(5): 545-50. [Abstract] [Full-text]
37. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
    Eur J Nucl Med Mol Imaging, 32(5): 593-600. [Abstract] [Full-text]
38. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?
    Acta Neurol Scand, 111(6): 353-9. [Abstract] [Full-text]
39. An exploration of the decision-making processes at the point of referral to an Admiral Nurse team.
    J Psychiatr Ment Health Nurs, 12(3): 359-64. [Abstract] [Full-text]
40. Adverse factors and the mental health of older people: implications for social policy and professional practice.
    J Psychiatr Ment Health Nurs, 12(3): 290-6. [Abstract] [Full-text]
41. Predictive genetic testing for Alzheimer's disease: impact upon risk perception.
    Risk Anal, 25(2): 397-404. [Abstract] [Full-text]
42. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe.
    Nat Biotechnol, 23(5): 577-83. [Abstract] [Full-text]
43. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization.
    Nucl Med Biol, 32(4): 337-51. [Abstract] [Full-text]
44. Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease.
    Nucl Med Biol, 32(4): 329-35. [Abstract] [Full-text]
45. Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial.
    J Am Geriatr Soc, 53(5): 793-802. [Abstract] [Full-text]
46. Alzheimer disease and mortality: a 15-year epidemiological study.
    Arch Neurol, 62(5): 779-84. [Abstract] [Full-text]
47. Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals.
    Arch Neurol, 62(5): 774-8. [Abstract] [Full-text]
48. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease.
    Arch Neurol, 62(5): 770-3. [Abstract] [Full-text]
49. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study.
    Arch Neurol, 62(5): 758-65. [Abstract] [Full-text]
50. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Arch Neurol, 62(5): 753-7. [Abstract] [Full-text]
51. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Arch Neurol, 62(5): 721-8. [Abstract] [Full-text]
52. Lack of genetic association of cholesteryl ester transfer protein polymorphisms with late onset Alzheimers disease.
    Neurosci Lett, 381(1): 36-41. [Abstract] [Full-text]
53. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Immunol Rev, 205: 244-56. [Abstract] [Full-text]
54. The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains.
    Neuropathol Appl Neurobiol, 31(3): 314-24. [Abstract] [Full-text]
55. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology.
    Neuropathol Appl Neurobiol, 31(3): 270-9. [Abstract] [Full-text]
56. Preserved painting creativity in an artist with Alzheimer's disease.
    Eur J Neurol, 12(6): 419-24. [Abstract] [Full-text]
57. Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease.
    Cereb Cortex, 15(6): 732-9. [Abstract] [Full-text]
58. Novel mutations and repeated findings of mutations in familial Alzheimer disease.
    Neurogenetics, 6(2): 85-9. [Abstract] [Full-text]
59. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
    Med Hypotheses, 65(1): 123-37. [Abstract] [Full-text]
60. Semantic and phonemic sequence effects in random word generation: a dissociation between Alzheimer's and Huntington's disease patients.
    J Int Neuropsychol Soc, 11(3): 303-10. [Abstract] [Full-text]
61. Driver landmark and traffic sign identification in early Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(6): 764-8. [Abstract] [Full-text]
62. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism.
    Neurosci Lett, 381(3): 275-8. [Abstract] [Full-text]
63. Effect of oral administration of a whole formula diet on nutritional and cognitive status in patients with Alzheimer's disease.
    Clin Nutr, 24(3): 390-7. [Abstract] [Full-text]
64. Verb agreements during on-line sentence processing in Alzheimer's disease and frontotemporal dementia.
    Brain Lang, 94(2): 217-32. [Abstract] [Full-text]
65. Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography.
    Psychiatry Clin Neurosci, 59(3): 280-90. [Abstract] [Full-text]
66. Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients.
    Psychiatry Clin Neurosci, 59(3): 274-9. [Abstract] [Full-text]
67. MCMC multilocus lod scores: application of a new approach.
    Hum Hered, 59(2): 98-108. [Abstract] [Full-text]
68. Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease.
    Endocrinology, 146(6): 2774-81. [Abstract] [Full-text]
69. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.
    Exp Neurol, 194(1): 91-6. [Abstract] [Full-text]
70. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
    Curr Med Res Opin, 21(4): 483-8. [Abstract] [Full-text]
71. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
    Brain, 128: 1442-53. [Abstract] [Full-text]
72. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    J Pharmacol Exp Ther, 313(3): 1370-8. [Abstract] [Full-text]
73. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study.
    FEBS Lett, 579(13): 2759-66. [Abstract] [Full-text]
74. GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid.
    Neuroscientist, 11(3): 250-60. [Abstract] [Full-text]
75. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE).
    Mol Cell Neurosci, 29(2): 333-43. [Abstract] [Full-text]
76. Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain.
    Brain Res, 1045(1): 224-8. [Abstract] [Full-text]
77. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.
    Int J Exp Pathol, 86(3): 173-85. [Abstract] [Full-text]
78. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD).
    Int J Exp Pathol, 86(3): 161-71. [Abstract] [Full-text]
79. Metals and amyloid-beta in Alzheimer's disease.
    Int J Exp Pathol, 86(3): 147-59. [Abstract] [Full-text]
80. Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease.
    Int J Exp Pathol, 86(3): 139-45. [Abstract] [Full-text]
81. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?
    Int J Exp Pathol, 86(3): 133-8. [Abstract] [Full-text]
82. Evidence for intact selective attention in Alzheimer's disease patients using a location priming task.
    Neuropsychology, 19(3): 381-9. [Abstract] [Full-text]
83. Humoral immunity in brain aging and Alzheimer's disease.
    Brain Res Brain Res Rev, 48(3): 477-87. [Abstract] [Full-text]
84. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
    Proc Natl Acad Sci U S A, 102(21): 7499-504. [Abstract] [Full-text]
85. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele.
    Clin Chem, 51(6): 944-51. [Abstract] [Full-text]
86. Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment.
    Neurobiol Aging, 26(8): 1193-8. [Abstract] [Full-text]
87. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
    Neurobiol Aging, 26(8): 1183-92. [Abstract] [Full-text]
88. Prion protein (PrPc) promotes beta-amyloid plaque formation.
    Neurobiol Aging, 26(8): 1177-82. [Abstract] [Full-text]
89. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice.
    Neurobiol Aging, 26(8): 1167-75. [Abstract] [Full-text]
90. Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease.
    Neurobiol Aging, 26(8): 1161-5. [Abstract] [Full-text]
91. ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala.
    Neurobiol Aging, 26(8): 1153-9. [Abstract] [Full-text]
92. Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.
    Neurobiol Aging, 26(8): 1145-51. [Abstract] [Full-text]
93. Estrogen receptor-alpha splice variants in the medial mamillary nucleus of Alzheimer's disease patients: identification of a novel MB1 isoform.
    J Clin Endocrinol Metab, 90(6): 3757-65. [Abstract] [Full-text]
94. Apolipoprotein epsilon4 is associated with more rapid decline in odor identification than in odor threshold or Dementia Rating Scale scores.
    Brain Cogn, 58(2): 178-82. [Abstract] [Full-text]
95. The relationships between television viewing in midlife and the development of Alzheimer's disease in a case-control study.
    Brain Cogn, 58(2): 157-65. [Abstract] [Full-text]
96. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease.
    Med Hypotheses, 65(2): 259-65. [Abstract] [Full-text]
97. Age-related impairments in operant DMTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease.
    Behav Brain Res, 161(2): 220-8. [Abstract] [Full-text]
98. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides.
    J Neurosci Methods, 145(1): 97-105. [Abstract] [Full-text]
99. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets.
    J Biol Chem, 280(22): 21522-30. [Abstract] [Full-text]
100. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron.
     J Biol Chem, 280(22): 20978-86. [Abstract] [Full-text]
101. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
     Neurosci Lett, 382(3): 338-41. [Abstract] [Full-text]
102. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
     Neurosci Lett, 382(3): 327-31. [Abstract] [Full-text]
103. The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression.
     Neurosci Lett, 382(3): 300-3. [Abstract] [Full-text]
104. Voxel-based morphometry to discriminate early Alzheimer's disease from controls.
     Neurosci Lett, 382(3): 269-74. [Abstract] [Full-text]
105. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease.
     Neurosci Lett, 382(3): 221-6. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.